Kybella is deoxycholic acid injection, approved in 2015 for one thing: improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. Fullness under the chin.
The label goes further than silence on other areas. It has a Limitation of Use that reads: "The safe and effective use of KYBELLA for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended."
That is an active statement, not a gap. It appears in the prescribing information and in the patient insert.
A clinician may still lawfully use an approved drug outside its approved indication. FDA regulates what manufacturers claim, not the practice of medicine. What off-label use means for you is that the evidence FDA reviewed does not cover what is being done, and the manufacturer's safety data does not cover it either. Separately, the American Society of Plastic Surgeons notes that it is illegal to commercially advertise an off-label use — so a clinic web page promoting "Kybella for armpit fat" is doing something the drug's own maker cannot do.
No published human study, case series or case report of deoxycholic acid injected into the axillary vault could be located: The axillary vault is the armpit hollow itself — the pocket under your arm.
That negative is scoped to this drug and this site. It comes from searches of the published medical literature for deoxycholic acid, ATX-101 and Kybella combined with axilla, axillary, periaxillary and armpit, plus the two systematic reviews of non-submental use, neither of which lists the axilla among treated sites.
The two reviews are the honest measure of how thin the off-label literature is overall. One found 10 articles meeting criteria across the whole body. The other found 11 cosmetic studies plus 8 case reports and concluded that "the overall recommendations for off-label uses are weak because of the lack of high-level studies."
There is one paper that clinics reach for. It is worth reading carefully rather than dismissing, because it is real data — just not data about the armpit.
Design: A retrospective chart review at a single private plastic surgery practice in New York, covering November 2015 to June 2017. 12 women. Not randomised, not controlled.
Target: anterior periaxillary fat. The paper defines it with four surface landmarks — the inner end of the lateral third of the collarbone, the start of the front armpit fold, the palpable junction of the upper outer breast with armpit skin, and the mid-armpit line. That is the fullness that sits in front of the armpit, on the chest wall, between the collarbone and the upper outer breast. It is not the armpit hollow.
Method: 2 mg per square centimetre, 0.2 mL per injection on a 1 cm grid, a 32 gauge half-inch needle, 8 to 10 mm deep. A mean of 1.8 treatments, mean 7.6 mL per treatment across both sides, mean total 13.9 mL.
Outcome: The clinician, the patient, and two blinded plastic surgeons looking at photographs all agreed a reduction had occurred. 10 of 12 women achieved a reduction and were satisfied. One was satisfied but never returned for photographs; one showed no reduction after a single treatment.
There was no volumetric, ultrasound, caliper or MRI measurement, and no validated rating scale: The outcome is agreement that a photograph looks different.
Side effects, all at the injection site: numbness in 12 of 12 (mean 18.6 days), swelling in 12 of 12 (mean 6.0 days), tenderness in 11 of 12 (mean 4.5 days), bruising in 5 of 12, firmness in 1. All resolved without lasting problems, and durations were shorter after later treatments.
The author receives writing assistance, medicines, equipment or administrative support from Allergan, and the medical writing was funded by an independent grant from Allergan.
And then the sentence that matters most: the paper's own safety argument was that, unlike the chin where the marginal mandibular nerve creates a no-treatment zone, "no anatomic structures such as nerves or major blood vessels are present in the anterior periaxillary region."
Read that as what it is: It is a claim about a specific, shallow, anterior plane on the chest wall. It is an argument for why that plane was chosen and why the armpit was not. It cannot be carried sideways into the axilla, where the opposite is true.
The axilla is a pyramid-shaped space under the shoulder, and it is full.
The brachial plexus: The bundle of nerves supplying the whole arm — passes through it.
The axillary artery and vein run through it.
The intercostobrachial nerve crosses it to supply sensation to the inner upper arm. The long thoracic and thoracodorsal nerves run along its walls to the muscles that stabilise the shoulder blade and pull the arm down.
The axillary lymph nodes sit in it. This is the densest superficial lymph node basin in the upper body, and it is the drainage field for the breast.
Now set that against what the Kybella label already says for the chin. Section 5.4 warns against injecting "into or in close proximity (1-1.5 cm) to salivary glands, lymph nodes and muscles", and says care must be taken to avoid injection directly into an artery or vein, "as it can result in vascular injury." The label's injection technique section adds that if resistance is felt on the way in — suggesting the needle has met fascia or non-fat tissue — the needle must be withdrawn to an appropriate depth before injecting.
Those instructions were written for a region with one nerve to avoid. The axilla contains several nerves, two major vessels, and the structures the label names as things to stay 1 to 1.5 cm away from: Vascular injury from inadvertent intravascular injection is a labelled post-marketing reaction for this drug, not a theoretical one.
None of this is a prediction that injecting the armpit causes harm. It is a description of why nobody has published doing it, and why the one adjacent published study went out of its way to define a plane where those structures are absent.
The armpit nodes are where breast tissue drains, and they are the nodes examined when breast cancer is staged. Whether injecting a fat-destroying detergent into that drainage field could complicate later assessment of those nodes is a question, not a finding. No published case or study of that happening has been located. It has not been studied either way, so it should not be presented as a known risk or dismissed as a non-issue.
What is on the label, and is not speculative, is the instruction not to inject into or within 1 to 1.5 cm of lymph nodes.
Clinics sometimes use "armpit fat" loosely for nearby areas. Two of those have small published reports, and they are worth separating out because the evidence differs.
Bra line and the fold behind the armpit: Two case reports. A 46-year-old woman treated on the upper back above the bra line, about 4 cm of fullness on each side, 2 mL per side in one session using 0.15 mL per injection at 0.5 to 1.0 cm spacing; and a 47-year-old treated on the outer breast in the region of the axillary tail, 1 mL per side. Both had mild swelling for 5 to 7 days. The author states the injections were given with utmost caution to avoid lymph nodes and nearby nerves and vessels. Two patients is two patients. Medical writing support and the open-access fee were funded by Allergan.
Upper arm: A case series of 4 women using diluted deoxycholic acid at 5 and 2.5 mg/mL — not the labelled 10 mg/mL — over 3 sessions, measured by tape and ultrasound. Fat thickness fell; arm circumference barely changed. Two authors are consultants or speakers for a pharmaceutical company.
Neither of these is the axilla either, and both are far too small to describe a complication rate.
Four questions do most of the work.
Which anatomical area do you mean?: Ask them to point to it and name it. Front of the armpit on the chest wall, the fold at the back, the bra line on the back, and the armpit hollow are four different places with four different evidence positions.
What is the published evidence for that exact area?: For the anterior periaxillary area the honest answer is one retrospective series of 12 women with photographic outcomes. For the armpit hollow the honest answer is nothing.
What is your plan for the lymph nodes and vessels?: The label says to stay 1 to 1.5 cm from lymph nodes and to avoid vessels. Ask how that is being achieved here.
Are you telling me this is off-label?: You should be told, in those words, and told that the drug's own label says use outside the submental region is not recommended.
Be told, explicitly, that this is off-label use of an approved drug, and that the label states use outside the area under the chin is not recommended.
Ask for a breast examination first if the area being treated is anywhere near breast tissue. The periaxillary study excluded women with cyclical periaxillary pain or swelling, because that can indicate accessory breast tissue rather than fat, and it used surface markings specifically to avoid the breast. A pinch test was used to confirm the tissue was subcutaneous fat at all.
Say if you have had breast surgery, breast cancer, lymph node surgery or radiotherapy on that side, or lymphoedema. This region is the breast's drainage field, and none of these situations has been studied with this drug.
Say if you take a blood thinner or antiplatelet drug, or have a bleeding disorder. Bruising affected 72 per cent of subjects in the submental trials and the label advises caution with these medicines.
The single labelled contraindication is infection at the injection site.
Ask what the total volume per session will be. The periaxillary author's own caution was to stay within approved dosing — not more than 10 mL per side per treatment and 0.2 mL per injection. A systematic review of side effects found that larger injected volumes were more likely to cause severe effects.
Fever with spreading redness, warmth or pus from an injection site. Injection-site infections with this drug have included cellulitis and abscess requiring intravenous antibiotics and surgical drainage.
Sudden severe pain, skin that turns white, dusky or purple, or a rapidly darkening patch at an injection site. Vascular injury from inadvertent injection into a vessel is a labelled post-marketing reaction.
Difficulty breathing, or a spreading rash with swelling. Hypersensitivity reactions including rash, hives and itching are labelled post-marketing reactions.
New weakness in the arm or shoulder, or numbness spreading down the inner upper arm rather than staying at the injection sites.
An open sore, drainage or an ulcer appears at an injection site. The label attributes ulceration and tissue death to injections placed too superficially, into the skin rather than the fat.
A firm lump appears and is not settling. Nodules are a labelled reaction and lasted a median of 23 days in the submental trials; firmness lasted a median of 28 days.
Numbness is still there well beyond six weeks. Median numbness after submental treatment was 43 days, and it was universal but shorter, a mean of 18.6 days, in the 12-woman periaxillary series.
Hair thins or disappears at an injection site. This is a labelled reaction and the label says it may persist.
Swelling in the arm on the treated side.